バイオシミラーの世界市場：組換非グリコシル化タンパク質、組換グリコシル化タンパク質、組換ペプチド...市場調査レポートについてご紹介

1 Introduction (Page No. – 15)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Market Segmentation
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders

2 Research Methodology (Page No. – 19)
2.1 Market Size Estimation
2.2 Market Breakdown and Data Triangulation
2.3 Market Share Estimation
2.4 Key Data From Secondary Sources
2.5 Key Data From Primary Sources
2.6 Key Industry Insights
2.7 Assumptions for the Study

3 Executive Summary (Page No. – 29)
3.1 Introduction

4 Premium Insights (Page No. – 33)
4.1 Biosimilars Market
4.2 Biosimilars Market, By Type
4.3 Geographical Snapshot of the Biosimilars Market
4.4 Biosimilars Market, By Type
4.5 Recombinant Nonglycosylated Proteins Market, By Type
4.6 Lifecycle Analysis, By Region

5 Market Overview (Page No. – 38)
5.1 Introduction
5.2 Biosimilars Market Segmentation
5.2.1 Biosimilars Market Segmentation, By Product
5.2.2 Biosimilars Market Segmentation, By Application
5.2.3 Biosimilars Market Segmentation, By Region
5.3 Market Dynamics
5.3.1 Market Drivers
5.3.1.1 Growing Pressure to Curtail Healthcare Expenditure
5.3.1.2 Increasing Demand for Biosimilars Drug Due to Their Cost-Effectiveness
5.3.1.3 Rising Incidences of Diseases
5.3.1.4 Rise in Aging Population Triggers the Incidences of Chronic Disorders
5.3.1.5 Strategic Collaborations Lead to Enhance Productivity and Clinical Trial Activities for Biosimilars
5.3.1.6 Increasing Government Support and Initiatives to Develop and Promote Biosimilars
5.3.2 Market Restrains
5.3.2.1 High Manufacturing Complexities and Costs
5.3.2.2 Innovative Strategies By Biologic Drug Manufacturers
5.3.2.3 Stringent Regulatory Requirements to Adversely Affect Investments in Biosimilars
5.3.3 Opportunities
5.3.3.1 Emerging Markets
5.3.3.2 Untapped Indications
5.3.3.3 Biologic Products Set to Be Off-Patent Will Offer Opportunities for Biosimilars
5.3.4 Burning Issues
5.3.4.1 Product Withdrawals Provide Significant Opportunities for New Entrants

6 Industry Insights (Page No. – 52)
6.1 Porter’s Five Forces Analysis
6.1.1 Threat From New Entrants
6.1.2 Threat of Substitutes
6.1.3 Intensity of Rivalry
6.1.4 Bargaining Power of Suppliers
6.1.5 Bargaining Power of Buyers
6.2 Key Pipeline Products
6.3 Regulatory Outlook
6.3.1 U.S.
6.3.2 Canada
6.3.3 Europe
6.3.4 Asia-Pacific
6.3.5 China
6.3.6 India
6.3.7 Japan
6.3.8 South Korea
6.3.9 Rest of the World
6.3.10 Brazil
6.3.11 Mexico
6.3.12 Argentina
6.3.13 Saudi Arabia
6.4 Biosimilars Services Industry Insights
6.4.1 Introduction
6.4.2 Contract Manufacturing Organizations
6.4.3 Contract Research Organizations
6.4.4 Other Services (Nonclinical & Bioinformatics)

7 Biosimilars Market, By Type of Product (Page No. – 63)
7.1 Introduction
7.2 Recombinant Non-Glycosylated Proteins
7.2.1 Insulin
7.2.2 Recombinant Human Growth Hormone (RHGH)
7.2.3 Granulocyte Colony-Stimulating Factor (Filgrastim)
7.2.4 Interferons
7.3 Recombinant Glycosylated Proteins
7.3.1 Erythropoietin (EPO)
7.3.2 Monoclonal Antibodies (MABS)
7.3.3 Follitropin
7.4 Recombinant Peptides
7.4.1 Glucagon
7.4.2 Calcitonin

8 Biosimilars Market, By Application (Page No. – 85)
8.1 Introduction
8.2 Oncology
8.3 Blood Disorders
8.4 Chronic and Autoimmune Diseases
8.5 Growth Hormone Deficiency
8.6 Infectious Diseases
8.7 Other Applications

9 Biosimilars Market, By Region (Page No. – 93)
9.1 Introduction
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 U.K.
9.3.2 Germany
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Rest of Europe
9.4 Asia-Pacific
9.4.1 China
9.4.2 India
9.4.3 Japan
9.4.4 South Korea
9.4.5 Rest of Asia-Pacific (ROAPAC)
9.5 Rest of the World (RoW)

10 Competitive Landscape (Page No. – 124)
10.1 Overview of Biosimilars
10.2 Market Share Analysis
10.3 Competitive Situation and Trends
10.3.1 New Product Launches and Regulatory Approvals
10.3.2 Agreements and Collaborations
10.3.3 Expansions
10.3.4 Acquisitions
10.3.5 Other Developments

11 Company Profiles (Page No. – 132)
11.1 Introduction
11.2 Hospira, Inc.
11.2.1 Business Overview
11.2.2 Product Offerings
11.2.3 Recent Developments
11.2.4 MnM View
11.3 Roche Diagnostics (A Division of F. Hoffmann-La Roche Ltd.)
11.3.1 Business Overview
11.3.2 Product Offerings
11.3.3 Recent Developments
11.4 Sandoz International GmbH (A Division of Novartis International Ag)
11.4.1 Business Overview
11.4.2 Product Offerings
11.4.3 Recent Developments
11.4.4 MnM View
11.5 Teva Pharmaceutical Industries Ltd.
11.5.1 Business Overview
11.5.2 Product Offerings
11.5.3 Recent Developments
11.5.4 MnM View
11.6 Amgen
11.6.1 Business Overview
11.6.2 Product Offerings
11.6.3 Recent Developments
11.7 Biocon Ltd.
11.7.1 Business Overview
11.7.2 Product Offerings
11.7.3 Recent Developments
11.8 Dr. Reddy’s Laboratories
11.8.1 Business Overview
11.8.2 Product Offerings
11.8.3 Recent Developments
11.9 Celltrion, Inc.
11.9.1 Business Overview
11.9.2 Product Offerings
11.9.3 Recent Developments
11.10 Mylan, Inc.
11.10.1 Business Overview
11.10.2 Product Offerings
11.10.3 Recent Developments
11.11 Merck KGAA
11.11.1 Business Overview
11.11.2 Product Offerings
11.11.3 Recent Developments

12 Appendix (Page No. – 156)
12.1 Discussion Guide
12.2 Introducing RT: Real-Time Market Intelligence
12.3 Available Customizations
12.4 Related Reports of Biosimilars